The ROS-1 NSCLC current market is mainly dominated by tyrosine kinase inhibitors such as XALKORI at present and is anticipated to be dominated by Repotrectinib, Taletrectinib, and NVL-520 by 2034.
The drug is under Priority Review by the U.S. Food and Drug Administration (FDA) and has a Prescription Drug User Fee Act (PDUFA) date of June 23, 2025 NEW YORK--(BUSINESS WIRE)--Nuvation Bio Inc.
NEW YORK--(BUSINESS WIRE)-- Nuvation Bio Inc. (NUVB), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced that Japan’s Ministry of Health ...
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a clinical-stage global biopharmaceutical company committed to developing novel cancer therapies, today announced that the first patient ...
Zidesamtinib is an investigational, novel brain-penetrant ROS1-selective inhibitor created with the aim to overcome limitations observed with currently available ROS1 inhibitors. Zidesamtinib is ...
Application based on data from the registrational TRIDENT-1 and CARE trials showing robust responses and durable activity in these patient populations If approved, repotrectinib will offer a potential ...
Sustained durability of responses demonstrated in both TRUST-I and TRUST-II with additional follow-up time TKI-naïve patients in TRUST-I achieved a median progression-free survival of 44.6 months; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback